Last updated: 2026-09-08 05:12:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.98, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.61 to $1.40. This page covers its latest market performance, valuation, price trends and company information.
-- | |
$0.94 | |
$1.40 | |
$0.61 | |
$0.94 | |
28.05K | |
12.44K | |
-- | |
$1.40 | |
$0.61 | |
-- | |
-- |
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) last closed at $0.94 as of 2026-09-04 20:05:00, unchanged from the previous close of $0.94.
During the latest regular trading session, BCTXL traded between $0.61 and $1.40, with a volume of 28.05K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) moved from $1.03 to $0.98, representing a decline of 4.85% ($0.05).
The stock traded between $0.87 and $1.03 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 11.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 46.8%
BCTXL is currently trading at $0.98, placing it 46.8% of the way from its 52-week low of $0.61 to its 52-week high of $1.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.